mProX™ Human TIGIT Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TIGIT, or T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains, has been studied in various applications. In upper tract urothelial carcinoma (UTUC), TIGIT was found to be the second most represented immune checkpoint, with a median expression rate on tumor-infiltrating CD4+ T cells of 25% and 2.9% on circulating CD4+ T cells. It also showed expression on tumor-infiltrating CD8+ T cells. In head and neck squamous cell carcinoma (HNSCC), a predictive model involving TIGIT was constructed to predict tumor immune cell infiltration and drug sensitivity. The low-risk HNSCC group showed higher expression of TIGIT. In a phase I dose escalation study, the anti-TIGIT monoclonal antibody ociperlimab was used in combination with tislelizumab in patients with advanced solid tumors. The study evaluated the safety, pharmacokinetics, and preliminary antitumor activity of the combination therapy. In a study on cancer immunotherapy, a supramolecular bispecific cell engager (Supra-BiCE) targeting TIGIT was developed to augment natural killer (NK) and T cell-based immunotherapy. The Supra-BiCE interacted with NK/T cells via TIGIT and showed enhanced binding affinities to TIGIT within tumor regions. Finally, in pancreatic cancer, S100P was identified as a potential biomarker for an immunosuppressive microenvironment. S100P expression was negatively correlated with immune cell infiltration, particularly CD8+ T cells, and showed a correlation with TIGIT expression. These studies highlight the diverse applications of TIGIT in cancer research and immunotherapy.